Future Medicine Archives - Page 16 of 16

Synthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases

June 10, 2019 Anti-inflammatory properties, Arthritis, Autoimmunity, Cannabinoids, Cannabis Science, CB1, CB2, Future Medicine, Muscle Pain, Neuropathy, Science, Synthetic Cannabinoids

Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses

A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.

View this review (yellow link) or download:

Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists Download

This paper is also stored here: http://bit.ly/2HZ6cWb inside the CED Foundation Archive

To explore related information, click keywords:

Market Projections, Ethanol Extraction, and Mismatched Expectations

June 7, 2019 Cannabis, Cannabis News, Extraction, Future Medicine, News, Processing, Products

While most people tout market projections, this CEO notes that many people entering the industry have not considered the logistics behind creating and expanding their business. In such a unique industry, realistic goals and measures will be crucial to long term success and scaling. http://bit.ly/31fJYH0

France to launch medical cannabis experiment in coming weeks

June 5, 2019 Cannabis, Cannabis News, France, Future Medicine, Legislation

As a nearly unanimous French Senate gave medical marijuana the green light on May 28, France will start experimenting with the use of medical marijuana for “about two years.” According to patient groups, somewhere between 300,000 and 1 million patients could be eligible to use cannabis to manage symptoms of cancer, certain types of epilepsy, multiple sclerosis, palliative care, and pain that does not respond to usual treatments. #france #cancer #epilepsy #multiplesclerosis #palliativecare #pain http://bit.ly/2WehBoY

A Flavonoid, Silymarin, Shows Therapeutic Activity in Tuberculosis

June 3, 2019 Cannabis Science, Flavonoids, Future Medicine, Science

Silymarin is a natural compound called a flavonoid, which happens to have antioxidant and liver protecting activities. Over many years, it has been proposed as a complementary medicine to reduce the liver injury produced by other medications. Interestingly, it happens to have anti-inflammatory properties and the ability to kill some bacteria. This flavonoid, Silymarin, is found in Milk Thistle… as well as Cannabis..and it seems to have “a significant therapeutic effect []administered alone, or in combination with chemotherapy, in [helping to treat] tuberculosis caused by drug-sensitive or drug-resistant strains[, findings represented here in both] in vitro and in vivo studies”

For many years, Tuberculosis (TB) has been a devastating public health problem, internationally. The treatment of this bacteria has been very limited and loaded with challenges. There is a constant cat/mouse chase between nature and human medicine, as the bacteria continually evolves to out-compete new drugs that are developed to treat it.

Here, yet another amazing potential breakthrough that cannabis brings to the table. Among the other flavonoids besides Silymarin: Orientin, Quercetin, and Kaempferol.

Of note: Silymarin happens to inhibit some liver enzymes, CYP-3A4 and CYP-2C9, which happen to be some of the liver enzymes which help break down cannabis metabolites.

This paper is stored here: http://bit.ly/2IgOLiG inside the CED Foundation Archive

To explore related literature, click keywords below the images: